Diabetes, weight and hormones

383 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Diabetes, weight and hormones
Treatment and conditionWhere it standsTrials
0.75% Phentolamine Ophthalmic Solution for vitamin a deficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Agbs for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AI-Guided Multimodal Rehabilitation Program for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Alcohol beverage for ketosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 100 mg TID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 125 mg BID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 125 mg TID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 150 mg BID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 75 mg BID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AP306 75 mg TID for hyperphosphatemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apitegromab for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
arabinoxylan for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ARBs in combination of SGLT2i for diabetes mellitusPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATR-258 for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATR-258 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autoinjector + EVOLOCUMAB for hypercholesterolemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Autoinjector + EVOLOCUMAB for hyperlipoproteinemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Autoinjector + Maridebart Cafraglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avexitide for glucose metabolism disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Avexitide for hypoglycemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
AZD6234 for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD6234 for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Barley beta-glucan(3.0g) for hyperlipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Barley beta-glucan(3.0g) for overweightTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Baxdrostat for hyperaldosteronismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
BBI-001 for hemochromatosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type iPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Berberine ursodeoxycholate for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
Berobenatide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Berobenatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Beta glucan for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet. for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BI 1820237 for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BI 1820237 + Placebo for BI 1820237 + Placebo for BI 456906 + Survodutide for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BI 3034701 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bimagrumab for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester) for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood and adrenaline for severe acute malnutritionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Body Composition + Blood Draw + CGM/CKM + gradCPT + Ketogenic Diet + Ketone/Glucose Monitoring + NIH Toolbox + PHQ-9 + Resting-state fMRI + SKID + Sleep Monitoring + Task-fMRI + WHO-5 for ketosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bread with added beta-glucans for dyslipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bread with added beta-glucans for hyperglycemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bread with added beta-glucans for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bread with added beta-glucans for obesity, abdominalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cagrilintide for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cagrilintide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Cagrilintide and Semaglutide + Placebo for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CagriSema for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
CagriSema (Cagrilintide B + semaglutide I) for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CagriSema (Cagrilintide B + semaglutide I) + Low Energy Diet for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Calorie restricted diet and exercise intervention for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Calorie restriction via total food replacement for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Calorie restriction via total food replacement for obesity, morbidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
cfMSC therapy for diabetes for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
cfMSC therapy for diabetes for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cholecalciferol for vitamin d deficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Ci + ends for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CI + No ENDS for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CIL001 (Paliroden) for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clofutriben for cushing syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clofutriben for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Comprehensive weight loss + Enhanced lifestyle changes + Naltrexone-Bupropion + Phentermine-Topiramate for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Comprehensive weight loss + Enhanced lifestyle changes + Semaglutide + Tirzepatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Control for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Control for dyslipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CoolSculpting® System for lipid metabolism disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Counseling + Phone calls + Self-monitoring tools + Text Messages for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cryolipolysis for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
cryolipolysis and aerobic exercise for obesity, abdominalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cryolipolysis device for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CTX310 for homozygous familial hypercholesterolemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CTX310 for hypercholesterolemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CTX310 for hyperlipoproteinemia type vPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Culturally Tailored Diabetes Prevention Program for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Culturally Tailored Diabetes Prevention Program for prediabetic statePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for prediabetic statePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyanocobalamin for vitamin b 12 deficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danuglipron for diabetes mellitusPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danuglipron for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin + Elecoglipron for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin plus Glucophage (MET ER) for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dapagliflozin propanediol for iron deficienciesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
delayed APM group recruit participants with symptoms lasting for more than 6 months for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Desiccated Porcine Thyroid Extract Tablets for hypothyroidismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diet Management + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Diet-as-Usual (DAU) + LCHF Ketogenic Diet for ketosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Diet-as-Usual (DAU) + LCHF Ketogenic Diet for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dietary vitamin D for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Digital Intervention + Metformin for prediabetic statePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
digital prosthetic interface technology for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DMR Procedure for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
DMR Procedure (Fractyl) for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
DR10624 Injection for hypertriglyceridemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Dulaglutide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Early arthroscopic partial menisectomy group for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for iron overloadPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ecnoglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)8
Efzimfotase Alfa for hypophosphatasiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elecoglipron for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Elecoglipron for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Electronic Cigarettes (EC) for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Eloralintide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Eloralintide for metabolic diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eloralintide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)13
Eloralintide + Macupatide for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eloralintide + Macupatide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Eloralintide + Tirzepatide for metabolic diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eloralintide + Tirzepatide for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
eloralintide and tirzepatide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
eloralintide and tirzepatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Empagliflozin for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Empagliflozin for ketosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ends + ni for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide for hypercholesterolemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide for hyperlipidemiasPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide Chloride for hypercholesterolemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide Decanoate for hypercholesterolemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
Enlicitide Decanoate for hyperlipoproteinemia type iiPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
EQW plus DAPA for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evolocumab for hypercholesterolemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Exenatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exercise for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exercise for dyslipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exploratory test group for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ezetimibe or ezetimibe-statin combination therapy for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ezetimibe or ezetimibe-statin combination therapy for dyslipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
fecal microbiota transplantation from healthy lean donors for metabolic syndromeTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Fixed-Dose Combination Strategy for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fixed-Dose Combination Strategy for dyslipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food Security Screening & Referral Program for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Food-based diet for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food-based diet for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Formula diet for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Formula diet for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Formulation A + Formulation B6 for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Freshly reconstituted MDCF-2 ingredients for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GnRH antagonist + Letrozole for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Green coffee + beta-glucan for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Green coffee + beta-glucan for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Green coffee extract for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Green coffee extract for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Group Therapy Program for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Group Therapy Program + naltrexone and bupropion (combination) for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Group Therapy Program + Phentermine-Topiramate for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Group Therapy Program + Semaglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
gut-brain axis (GLP-1)-activating food carbohydrate for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for metabolic diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haploidentical Hematopoietic Cell Transplantation for metabolic diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HD-6277 100mg for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HD-6277 25mg for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HD-6277 50mg for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
High-intensity Mediterranean diet intervention for hyperlipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High-intensity Mediterranean diet intervention for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High-intensity Mediterranean diet intervention for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Home Based Physical Exercise + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HRS9531 for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
HRS9531 Injection for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
HRS9531 injection;Placebo for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HS-20094 Injection for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Hyperpolarized 13C-pyruvate for metabolic syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
icovamenib 100 mg for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
icovamenib 100mg for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
IN-B00009 for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inclisiran for hyperlipidemiasPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Insulin efsitora alfa for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)12
Insulin efsitora alfa for insulin resistancePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intensified medical follow-up and glucose-lowering drugs for prediabetic stateTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intensive lifestyle Intervention for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intensive lifestyle Intervention + Meal replacement system for diabetes mellitus, type 2Trials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Intensive lifestyle Intervention + Meal replacement system for obesityTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Intermittent energy restriction (IER) for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intermittent fasting 5:2 + Low-carbohydrate diet + Total diet replacement for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intraoral Negative Pressure Therapy + Oral Appliances + Positional Therapy + Surgery + Tongue Muscle Strength Training for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivm for ovarian hyperstimulation syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
K-757 120 mg BID and K-833 100 mg BID for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
K-757 120 mg BID and matching placebo to K-833 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
K-757 and K-833 for diabetes mellitus, type 2Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
K-757 and K-833 for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
K-757 and K-833 BID + K-757 and K-833 QD for diabetes mellitus, type 2Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
K-757 and K-833 BID + K-757 and K-833 QD for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Kenetik for ketosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketogenic Diet for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ketogenic Diet for ketosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ketogenic Diet for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ketogenic diet intervention for ketosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Laroprovstat for dyslipidemiasPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCHF Ketogenic Diet for ketosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
libitum diet and waiting list control group for metabolic syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Liraglutide for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Liraglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Liver-expressed antimicrobial peptide 2 for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lns for infant nutrition disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lns for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
low calorie diet + Phentermine/topiramate for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-calorie MIND-HK diet for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Macupatide for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Macupatide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
MAR001 for hypertriglyceridemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maridebart Cafraglutide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Maridebart Cafraglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Maridebart Cafraglutide for overweightPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching placebo to K-757 and matching placebo to K-833 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Garetosmab + Semaglutide + TREVOGRUMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Trevogrumab + Semaglutide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB + GARETOSMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mazdutide for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MDCF-2 shelf-stable foil pouch prototype with green banana powder for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MDCF-2 shelf-stable foil pouch prototype with sweet potato for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Meal Replacement Therapy for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Meglumine sodium succinate for diabetic ketoacidosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MET097 for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metreleptin for insulin resistancePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MiniMed 670G system for hypoglycemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MKP10241 for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MKP10241 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Modified delineation for thyroid diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
mRNA-3927 for acidosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
mRNA-3927 for propionic acidemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
MT1013 for hyperparathyroidism, secondaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Napazimone for mitochondrial diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neovasculgen® for diabetes mellitusPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
NI + No ENDS for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nicotine replacement therapy (NRT) for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NNC0487-0111 for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemiasPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olezarsen for hyperlipoproteinemia type iPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Oral appliance therapy for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oral BGE-102 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Orforglipron for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)15
Orforglipron for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)16
Osilodrostat for adrenal hyperplasia, congenitalPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osilodrostat for cushing syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Oxytocin for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oxytocin for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)5
Oxytocin for pediatric obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Parathyroid Allotransplant for hypoparathyroidismPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patiromer for hyperkalemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemvidutide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Petrelintide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-06882961 (Cohort 3) for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-06882961 (Cohorts 1 and 2) for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08653944 for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08653944 for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PG-102 for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine for pediatric obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for sexual infantilismPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine / Topiramate Oral Product for glucose intolerancePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine / Topiramate Oral Product for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine-Topiramate for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine-Topiramate ER for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Photobiomodulation for obesity, morbidPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo (for Syntocinon) + Oxytocin for sexual infantilismTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo (matched to semaglutide) + Zenagamtide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Eloralintide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Eloralintide + Macupatide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Eloralintide + Tirzepatide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + MAZDUTIDE for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Naperiglipron for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Oxytocin for obesityTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Reduced-calorie diet + Tirzepatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Standardized diet and physical activity counseling throughout the study. + Retatrutide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo Nasal Spray for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
placebo with matching dosage + ECNOGLUTIDE for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for hyperlipidemiasTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for disorders of sex developmentPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex developmentPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex developmentPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Qsymia for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Qsymia 11.25Mg-69Mg Extended Release Capsule + Qsymia 15Mg-92Mg Extended Release Capsule + Qsymia 3.75Mg-23Mg Extended Release Capsule + Qsymia 7.5Mg-46Mg Extended Release Capsule for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Qsymia and lifestyle management therapy for pediatric obesityTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
RAY1225 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ready-to-use supplementary food (RUSF) arm for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Relacorilant for cushing syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Relacorilant for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Relacorilant for insulin resistanceTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
responsive neurostimulation for obesity, morbidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for diabetes mellitusPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Retatrutide for insulin resistancePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for metabolic diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)12
Ribupatide for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RP-A501 for lysosomal storage diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for diabetes mellitusPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Semaglutide for glucose intolerancePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)20
Semaglutide for pediatric obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for prediabetic statePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Semaglutide + BIMAGRUMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide + Cagrilintide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Semaglutide + Cagrilintide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Semaglutide + TREVOGRUMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide + TREVOGRUMAB + GARETOSMAB for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sernova Cell Pouch for hypoglycemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHR-1918 for homozygous familial hypercholesterolemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Silkworm pupa tablets for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sodium zirconium cyclosilicate for hyperkalemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for malnutritionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Structured weight-loss program for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Structured weight-loss program for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sun Exposure + Vitamin D3 Supplements for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)15
Test group for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Testosterone for eunuchismPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Testosterone enanthate for eunuchismPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tifeglipron for diabetes mellitus, type 2Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Time Restricted Eating (TRE) for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Time Restricted Eating As Treatment (TREAT) for Diabetes. for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Time restricted feeding for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Time-restricted eating for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Time-restricted eating for overweightTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for diabetes mellitusPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Tirzepatide for dyslipidemiasPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for metabolic diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirzepatide for metabolic syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tirzepatide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)23
Tirzepatide for prediabetic statePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Topical Simvastatin 2% Cream for xanthomatosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Diet Replacement for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Diet Replacement for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Diet Replacement (800kcal/day) for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Diet Replacement (TDR) Program for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Diet Replacement (TDR) Program for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for iron deficienciesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Treatment with Ketone Supplement for ketosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Treatment with Placebo for ketosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Treosulfan for nijmegen breakage syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trevogrumab for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
UBT251 Injection 2.0 mg and UBT251 Injection Placebo for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 Injection 4.0 mg for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 Injection 6.0 mg for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBT251 Injection 6.0 mg and UBT251 Injection Placebo for obesityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ultrasound lipolysis for obesity, abdominalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Upacicalcet for hyperparathyroidism, secondaryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for hypercholesterolemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for hyperlipoproteinemia type iiPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Very Low-calorie MIND-HK diet for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
VI-0521 for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VI-0521 for obesity, morbidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VI-0521 Mid Dose for pediatric obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VI-0521 oral capsule for pediatric obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
VI-0521 Top Dose for pediatric obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vicadrostat for diabetes mellitus, type 2Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Virtual Weight Management Coaching + Semaglutide for obesityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Vitamin d for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin D supplementation for diabetes mellitusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vitamin D supplementation for vitamin d deficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VX-017 for hypoglycemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
WS016 for hyperkalemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
WVE-007 for obesityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zeltiq CoolSculpting device for obesityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zenagamtide for diabetes mellitus, type 2Trial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zimislecel for hypoglycemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1